Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

BLOCK PCNSL (NHL32) : An ALLG Phase II study of pembrolizumab checkpoint blockade following chemoimmunotherapy for primary central nervous system lymphoma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaB-Cell Non Hodgkin Lymphoma,Diffuse Large Cell Lymphoma,Lymphoma

Trial Overview Read MoreRead more

This phase II study is trying to determine if standard chemotherapy induction therapy followed by immunotherapy (pembrolizumab) will be effective in maintaining life expectancy with minimal side effects for people with primary central nervous system lymphoma.
 

This trial is treating patients with primary central nervous system lymphoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

An ALLG Phase II study of pembrolizumab checkpoint blockade following chemoimmunotherapy for primary central nervous system lymphoma

Cooperative Group

Australasian Leukaemia and Lymphoma Group (ALLG)

Commercial Sponsor

Merck

Summary

All participants in this trial will receive chemotherapy induction therapy (CIT) of either A) Rituximab, Methotrexate, Procarbazine & Vincristine (R-MPV) Cytarabine (Ara-C); or B) Cytarabine, Thiopeta & Rituximab (MATRix). The CIT given is at the discretion of the participant's clinician and is not assessed as part of this study. Once the induction treatment is complete, participants will receive Pembrolizumab immunotherapy (200mg via intravenous infusion) commencing 4-6 weeks after last CIT exposure, and administered every 3 weeks for 35 cycles/2 years.

Recruiting Hospitals Read MoreRead more

Austin Health
Heidelberg
Ms Samantha Chakar
samantha.chakar@austin.org.au
03 9496 3088

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next